The philosophy of this division is that clinical research is intimately linked to excellence in clinical care.

Clinical trial delivers innovation in cardiovascular medical and device management through dynamic team of practitioners. With cardiovascular disease dominating the cause of mortality and mobility in this regional and US overall, clinical trials evaluate therapies for heart failure, coronary disease and rhythm disorders. It allows clinicians and patients to access evidence based cardiovascular care and device management.

Principle investigator:

• Joseph R. Alonso, MD FACC

Sub-Investigators:

• Tong Liu, MD,PhD, FACC
• Ajay Mehta, MD
• Vijay K. Mittal, MD FACC

Research Trial Coordinator:

• Karen Perry
  (352) 816-0476   karen@ehsfamily.com

Currently Enrolling For The Below Clinical Trials

Contrast Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention: APX-115 drug study to determine the occurrence of acute kidney injury in patients undergoing coronary stenting

Ulcerative Colitis: Abivax- a drug candidate with a new mechanism of action for patients with moderate to severe Ulcerative Colitis

 

---

Principle investigator:

• Lan Luo, MD FACC

Research Trial Coordinator:

• Arleana Brown
  (352) 421-5316   arleana.brown@morganmmc.com

Currently Enrolling For The Below Clinical Trials

Acute Coronary Syndrome: A study to evaluate the effects of dalcetrapib on reducing cardiovascular risk for patients with a recent Acute Coronary Syndrome (ACS)

Heart Failure with Systemic Inflammation: A study to evaluate the effects of ziltivekimab for patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.

Heart Failure with Preserved EF**: A study to evaluate the efficacy and safety of the combined use of oral BI 690517 and empagliflozin in patients with symptomatic heart failure (NYHA II-IV) and left ventricular ejection fraction >40%

** Enrollment beginning 7/25/24